NCTC
SRPT icon

New Covenant Trust Company’s Sarepta Therapeutics SRPT Stock Holding History

New Covenant Trust Company’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-249
Closed -$32.2K – 362
2024
Q1 		$32.2K Buy
+249
New +$30.5K 0.03% 198

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

New Covenant Trust Company's SRPT Position: Q2 2024 in Review

New Covenant Trust Company sold out of Sarepta Therapeutics (SRPT) in Q2 2024, closing a stake of 249 shares — an estimated $32.2K sold.

New Covenant Trust Company first reported a position in SRPT in Q1 2024 and held it in 1 quarter. The position peaked at $32.2K in Q1 2024. 483 funds tracked by Wall St. Rank hold SRPT as of Q2 2024.

  • New Covenant Trust Company reported no remaining Sarepta Therapeutics position as of Q2 2024 after selling out during the quarter.
  • New Covenant Trust Company sold 249 Sarepta Therapeutics shares in Q2 2024, an estimated $32.2K.
  • New Covenant Trust Company first reported a position in Sarepta Therapeutics in Q1 2024 and held it in 1 quarter.
  • New Covenant Trust Company's Sarepta Therapeutics position peaked at $32.2K in Q1 2024.
  • 483 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2024.

Based on New Covenant Trust Company's 13F filing for Q2 2024, filed 30 Jul 2024.